Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Revenue (ASC 606) of $1.38 million for fiscal year 2024.
NORTHWEST BIOTHERAPEUTICS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $1.38M | -28.5% |
| 2023 | $1.93M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $200.0K | -44.0% | +52.7% |
| June 30, 2025 | $131.0K | -74.3% | -65.1% |
| March 31, 2025 | $375.0K | +32.0% | +5.0% |
| September 30, 2024 | $357.0K | -12.1% | -30.0% |
| June 30, 2024 | $510.0K | +153.7% | +79.6% |
| March 31, 2024 | $284.0K | — | -30.0% |
| September 30, 2023 | $406.0K | — | +102.0% |
| June 30, 2023 | $201.0K | — | — |
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -28.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2024 period, NORTHWEST BIOTHERAPEUTICS INC’s revenue (asc 606) has declined by 28.5% (from $1.93 million to $1.38 million).
- The most recent figure is from NORTHWEST BIOTHERAPEUTICS INC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: